Athira Pharma, Inc.
ATHA · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.11 | 0.02 | 0.01 | 0.01 |
| FCF Yield | -28.59% | -59.28% | -131.80% | -115.16% |
| EV / EBITDA | 0.53 | 1.04 | 1.59 | 1.61 |
| Quality | ||||
| ROIC | -24.82% | -22.09% | -24.80% | -33.80% |
| Gross Margin | 0.00% | 0.00% | 0.00% | 0.00% |
| Cash Conversion Ratio | 0.71 | 1.00 | 1.60 | 1.73 |
| Growth | ||||
| Revenue 3-Year CAGR | -100.00% | -100.00% | -100.00% | -100.00% |
| Free Cash Flow Growth | 33.30% | 52.27% | 43.62% | -12.99% |
| Safety | ||||
| Net Debt / EBITDA | 2.90 | 2.79 | 2.84 | 3.08 |
| Interest Coverage | 0.00 | 0.00 | 0.00 | 0.00 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | 0.00 | -76.95 | -321.11 | 0.00 |